|
1
|
A "silent" polymorphism in the MDR1 gene changes substrate specificity.
|
Science
|
2006
|
15.18
|
|
2
|
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
|
Breast Cancer Res
|
2008
|
3.98
|
|
3
|
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
|
Proc Natl Acad Sci U S A
|
2011
|
1.97
|
|
4
|
Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database.
|
Mol Cancer Ther
|
2009
|
1.83
|
|
5
|
Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies.
|
Curr Mol Pharmacol
|
2008
|
1.46
|
|
6
|
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter.
|
Mol Cancer Ther
|
2007
|
1.13
|
|
7
|
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions.
|
Mol Pharm
|
2011
|
1.06
|
|
8
|
Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5).
|
FEBS J
|
2005
|
1.04
|
|
9
|
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
|
Clin Cancer Res
|
2012
|
0.94
|
|
10
|
Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor.
|
Mol Cancer Ther
|
2006
|
0.91
|
|
11
|
Evolution of drug resistance in cancer: the emergence of unique mechanisms and novel techniques.
|
Mol Pharm
|
2011
|
0.77
|